RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS)

被引：0
|
作者：
Garcia-Manero, G. [1 ]
Fenaux, P. [2 ]
Al-Kali, A. [3 ]
Baer, M. R. [4 ]
Sekeres, M. [5 ]
Roboz, G. [6 ]
Gaidano, G. [7 ]
Scott, B. [8 ]
Greenberg, P. [9 ]
Platzbecker, U. [10 ]
Steensma, D. P. [11 ]
Kambhampati, S. [12 ]
Kreuzer, K. A. [13 ]
Godley, L. [14 ]
Collins, R. [15 ]
Atallah, E. [16 ,17 ]
Azarnia, N. [18 ]
Petrone, M. E. [19 ]
Snyder, B. R. [20 ]
Maniar, M. [21 ]
Silverman, L. R. [22 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Hosp St Louis, Serv Hematol Seniors, Paris, France
[3] Mayo Clin, Dept Hematol, Rochester, MN USA
[4] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[5] Cleveland Clin, Dept Hematol Oncol & Blood Disorders, Cleveland, OH 44106 USA
[6] Weill Cornell Med Coll, Leukemia Serv, New York, NY USA
[7] Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Novara, Italy
[8] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA
[9] Stanford Med Sch, Dept Med Hematol, Stanford, CA USA
[10] Univ Klinikum Dresden, Med Klin & Poliklin 1, Dresden, Germany
[11] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[12] Univ Kansas, Med Ctr, Dept Internal Med, Westwood, KS USA
[13] Univ Klinikum Koln, Dept Internal Med, Cologne, Germany
[14] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA
[15] Univ Texas Dallas, Dept Internal Med, Dallas, TX 75230 USA
[16] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Div Hematol & Oncol, Milwaukee, WI 53226 USA
[17] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[18] Onconova Therapeut Inc, Dept Biometr, Newtown, PA USA
[19] Onconova Therapeut Inc, Dept Pharmacovigilance & Med & Sci Commun, Newtown, PA USA
[20] Onconova Therapeut Inc, Dept Med & Sci Commun, Newtown, PA USA
[21] Onconova Therapeut Inc, Prod Dev Dept, Newtown, PA USA
[22] Icahn Sch Med Mt Sinai, Dept Leukemia, New York, NY 10029 USA
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30113-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
112
引用
收藏
页码：S57 / S58
页数：2
相关论文
共 50 条
  • [31] Magrolimab plus Azacitidine Versus Azacitidine plus Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study
    Garcia-Manero, Guillermo
    Daver, Naval
    Xu, Jin
    Chao, Mark
    Chung, Trisha
    Tan, Anderson
    Wang, Yan
    Wei, Andrew
    Vyas, Paresh
    Sallman, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S343 - S344
  • [32] Clinical Outcome of 40 Patients with Higher-Risk Myelodysplastic Syndromes (MDS) after Treatment with Hypomethylating Agents: a Matched-Pairs Analysis.
    Nachtkamp, Kathrin
    Strupp, Corinna
    Kuendgen, Andrea
    Gattermann, Norbert
    Haas, Rainer
    Germing, Ulrich
    BLOOD, 2008, 112 (11) : 929 - 929
  • [33] Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups
    Wijermans, Pierre
    Suciu, Stefan
    Baila, Liliana
    Platzbecker, Uwe
    Giagounidis, Aristoteles
    Selleslag, Dominik
    Labar, Boris
    Salih, Helmut
    Beeldens, Filip
    Muus, Petra
    de Witte, Theo
    Luebbert, Michael
    BLOOD, 2008, 112 (11) : 90 - 90
  • [34] Decitabine vs. best supportive care in elderly higher-risk MDS patients with or without monosomal karyotypes: EORTC-LG/GMDS-SG phase III trial 06011
    Luebbert, M.
    Suciu, S.
    Hagemeijer, A.
    Platzbecker, U.
    Giagounidis, A.
    Selleslag, D.
    Germing, U.
    Salih, H. R.
    Muus, P.
    Bogatyreva, L.
    Aul, C.
    De Witte, T.
    Ganser, A.
    Huls, G.
    Marie, J. P.
    Wijermans, P.
    LEUKEMIA RESEARCH, 2013, 37 : S147 - S147
  • [35] Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
    Brunner, Andrew M.
    Esteve, Jordi
    Porkka, Kimmo
    Knapper, Steve
    Vey, Norbert
    Scholl, Sebastian
    Garcia-Manero, Guillermo
    Wermke, Martin
    Janssen, Jeroen
    Traer, Elie
    Loo, Sun
    Narayan, Rupa
    Tovar, Natalia
    Kontro, Mika
    Ottmann, Oliver
    Naidu, Purushotham
    Kurtulus, Sema
    Makofske, Jessica
    Liao, Serena
    Mohammed, Anisa
    Sabatos-Peyton, Catherine A.
    Rinne, Mikael L.
    Borate, Uma
    Wei, Andrew H.
    BLOOD, 2020, 136
  • [36] A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents
    Short, Nicholas J.
    Jabbour, Elias
    Naqvi, Kiran
    Patel, Ami
    Ning, Jing
    Sasaki, Koji
    Nogueras-Gonzalez, Graciela M.
    Bose, Prithviraj
    Kornblau, Steven M.
    Takahashi, Koichi
    Andreeff, Michael
    Sanchez-Petitto, Gabriela
    Estrov, Zeev
    Dinardo, Courtney D.
    Montalban-Bravo, Guillermo
    Konopleva, Marina
    Alvarado, Yesid
    Bhalla, Kapil N.
    Fiskus, Warren
    Khouri, Maria
    Islam, Rubiul
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (01) : 74 - 79
  • [37] OVERALL SURVIVAL (OS) AND BASELINE DISEASE CHARACTERISTICS IN MDS PATIENTS WITH PRIMARY HMA FAILURE IN A RANDOMIZED, CONTROLLED, PHASE III STUDY OF RIGOSERTIB
    Garcia-Manero, G.
    Fenaux, P.
    Al-Kali, A.
    Baer, M.
    Sekeres, M.
    Roboz, G.
    Gaidano, G.
    Scott, B.
    Greenberg, P.
    Platzbecker, U.
    Steensma, D.
    Kreuzer, K. -A.
    Godley, L.
    Collins, R.
    Atallah, E.
    Azarnia, N.
    Silverman, L.
    HAEMATOLOGICA, 2015, 100 : 238 - 238
  • [38] Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care
    Nazha, Aziz
    Sekeres, Mikkael A.
    Komrokji, Rami
    Steensma, David P.
    Kantarjian, Hagop
    Roboz, Gail
    Fenaux, Pierre
    Prebet, Thomas
    Azarnia, Nozar
    Zbyszewski, Patrick S.
    Fruchtman, Steven M.
    Santini, Valeria
    Silverman, Lewis R.
    Platzbecker, Uwe
    Garcia-Manero, Guillermo
    BLOOD CANCER JOURNAL, 2017, 7
  • [39] Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.
    Sallman, David Andrew
    Al Malki, Monzr M.
    Asch, Adam Steven
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel Aaron
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Gu, Lin
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol Elaine
    Lal, Indu
    Vyas, Paresh
    Daver, Naval Guastad
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care
    Aziz Nazha
    Mikkael A. Sekeres
    Rami Komrokji
    David P. Steensma
    Hagop Kantarjian
    Gail Roboz
    Pierre Fenaux
    Thomas Prebet
    Nozar Azarnia
    Patrick S. Zbyszewski
    Steven M. Fruchtman
    Valeria Santini
    Lewis R. Silverman
    Uwe Platzbecker
    Guillermo Garcia-Manero
    Blood Cancer Journal, 7
12345